BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Cancer Discov 2016 06 5;6(6):594-600. Epub 2016 Apr 5.

Foundation Medicine, Inc., Cambridge, Massachusetts.

Unlabelled: Neuroendocrine tumors comprise a heterogeneous group of malignancies with a broad spectrum of clinical behavior. Poorly differentiated tumors follow an aggressive course with limited treatment options, and new approaches are needed. Oncogenic BRAF V600E (BRAF(V600E)) substitutions are observed primarily in melanoma, colon cancer, and non-small cell lung cancer, but have been identified in multiple tumor types. Here, we describe the first reported recurrent BRAF(V600E) mutations in advanced high-grade colorectal neuroendocrine tumors and identify a BRAF alteration frequency of 9% in 108 cases. Among these BRAF alterations, 80% were BRAF(V600E) Dramatic response to BRAF-MEK combination therapy occurred in two cases of metastatic high-grade rectal neuroendocrine carcinoma refractory to standard therapy. Urinary BRAF(V600E) circulating tumor DNA monitoring paralleled disease response. Our series represents the largest study of genomic profiling in colorectal neuroendocrine tumors and provides strong evidence that BRAF(V600E) is an oncogenic driver responsive to BRAF-MEK combination therapy in this molecular subset.

Significance: BRAF(V600E) is an established oncogenic driver, but significant disparities in response exist among tumor types. Two patients with treatment-refractory high-grade colorectal neuroendocrine tumors harboring BRAF(V600E) exhibited rapid and durable response to combined BRAF-MEK inhibition, providing the first clinical evidence of efficacy in this aggressive tumor type. Cancer Discov; 6(6); 594-600. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 561.

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008024PMC
June 2016
52 Reads

Publication Analysis

Top Keywords

neuroendocrine tumors
20
colorectal neuroendocrine
16
combination therapy
12
braf-mek combination
12
high-grade colorectal
12
brafv600e mutations
8
brafv600e
8
tumor types
8
oncogenic driver
8
neuroendocrine
6
tumors
6
circulating tumor
4
brafv600e circulating
4
tumor dna
4
standard therapy
4
carcinoma refractory
4
refractory standard
4
dna monitoring
4
therapy urinary
4
urinary brafv600e
4

Similar Publications